Hostname: page-component-74656f9884-kv2lp Total loading time: 0 Render date: 2026-11-06T04:24:11.142Z Has data issue: false hasContentIssue false

Quantitative measurement of crystalline impurity in a pharmaceutical tablet by X-ray powder diffraction and method validation

Published online by Cambridge University Press:  05 June 2013

R. Casella*
Affiliation:
AstraZeneca Pharmaceuticals Inc., 35 Gatehouse Drive, Waltham, Massachusetts 02451
S. Boudreau
Affiliation:
AstraZeneca Pharmaceuticals Inc., retired
James A. Wesley
Affiliation:
Eli Lilly and Company, Lilly Research Laboratories, Drop Code 3832 -LTC North, North Indianapolis, Indianapolis 46285
Robert D'Aloise
Affiliation:
AstraZeneca Pharmaceuticals Inc., retired
*
a)Author to whom correspondence should be addressed. Electronic mail: robert.casella@astrazeneca.com

Abstract

A powder X-ray diffraction method was developed and validated to measure the crystalline impurity 4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide hydrate in a pharmaceutical tablet ranging from 0.6 to 3% (w/w). The calibration plot was found to be linear with a correlation coefficient (r2) of 0.996, and was reproducible among operators. The detection limit was determined to be 0.6% with a signal-to-noise ratio of 3:1. The quantitation limit was determined to be 1% with a signal-to-noise ratio of 5:1. Instrument precision at the quantitation limit was 5.8%. Method precision was 6.1% at the quantitation limit and 7.4% at the detection limit. Intermediate precision at the quantitation limit was 7.3% during a 6-month study. Accuracy measurements using crystalline impurity standards prepared in an excipient mixture ranged from 89.3 to 105.5%. Accuracy measurements using tablets containing spiked quantities of crystalline impurity ranged from 72.0 to 92.7%. Accuracy measurements using spiked tablets were complicated because the crystalline impurity was lost during the manufacturing process and a correction factor was used. Ruggedness was assessed by evaluating repetitive assay, repetitive packing, sample packing, and sample stability. Repetitive assays show the exposure of standards to a relative humidity in excess of 57% caused displacement error because of an increase in sample volume and a peak-position shift. Repetitive-packing studies show the analyte was extracted from the sample at a low relative humidity because of a static-charge induction. Sample-packing studies show that two subjective packing techniques were equivalent, and that under- and over-packing samples cause changes in sample density which would not affect results within ±16%. Sample-stability studies show that the quantitation-limit standard was stable as long as the sample was exposed to a relative humidity below 57%.

Information

Type
Technical Articles
Copyright
Copyright © International Centre for Diffraction Data 2013 
Figure 0

Figure 1. Structure of the crystalline impurity 4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide hydrate.

Figure 1

Figure 2. Crystalline impurity calibration plots (n = 3).

Figure 2

Table I. Regression statistics for the crystalline impurity calibration plot.

Figure 3

Figure 3. Calibration plots prepared and analyzed independently.

Figure 4

Figure 4. Crystalline impurity calibration plot prepared in lactose monohydrate.

Figure 5

Table II. Accuracy measurements from samples of the crystalline impurity prepared in an excipient mixture.

Figure 6

Table III. Accuracy measurements* from tablets spiked with crystalline impurity.

Figure 7

Figure 5. Thermogravimetric analysis of the crystalline impurity.

Figure 8

Figure 6. Crystalline impurity loss by dehydration in one hour.

Figure 9

Table IV. Method precision at the quantitation and detection limits (n = 6)

Figure 10

Table V. Intermediate precision at the quantitation limit (1% crystalline impurity).

Figure 11

Table VI. Five repetitive assays for crystalline impurity content in spiked tablets.

Figure 12

Figure 7. Temperature and humidity measurements throughout a repetitive assay.

Figure 13

Figure 8. Crystalline impurity spectra showing a shifted-peak position at 11.3 °2Θ and a normal-peak position at 11.2 °2Θ.

Figure 14

Table VII. Normal- and shifted-peak position statistics.

Figure 15

Figure 9. Packing replicates and crystalline impurity content.

Figure 16

Figure 10. Crystalline impurity spectra following exposure to ambient conditions for 10 days.

Figure 17

Table VIII. Sample over-packing and under-packing statistics.

Figure 18

Table IX. 1% crystalline impurity results during a 10-day exposure to ambient conditions (one sample).